Last reviewed · How we verify
Remifemin
Remifemin is a Small molecule drug developed by Zhejiang Cancer Hospital. It is currently in Phase 2 development. Also known as: cimicifuga racemosa, black cohosh.
Remifemin is a product containing Black Cohosh Extract, which has been studied for various conditions including menopause, hot flashes, osteoporosis, and anxiety disorders. The plant Black Cohosh, from which the extract is derived, is a flowering plant native to eastern North America, commonly found in woodland habitats.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Remifemin |
|---|---|
| Also known as | cimicifuga racemosa, black cohosh |
| Sponsor | Zhejiang Cancer Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature
- Assessing the Synergistic Effects of Black Cohosh, Soy Isoflavones, and SDG Lignans (Soloways TM) on Menopausal Symptoms (NA)
- A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ (NA)
- EFFICACY OF ANSA (Experimental Drug) & CRAN MAX (Control Drug) SACHET (PHASE3)
- Comparative Study to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Estradiol / Dydrogesterone in Perimenopausal Women (PHASE4)
- Effect of Menopause Relief EP-40 in Women With Menopausal Symptoms (PHASE2)
- Vascular Effect of CIMICIFUGA RACEMOSA (NA)
- Remifemin Preventing the Climacteric Symptoms in Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifemin CI brief — competitive landscape report
- Remifemin updates RSS · CI watch RSS
- Zhejiang Cancer Hospital portfolio CI
Frequently asked questions about Remifemin
What is Remifemin?
Who makes Remifemin?
Is Remifemin also known as anything else?
What development phase is Remifemin in?
Related
- Manufacturer: Zhejiang Cancer Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: cimicifuga racemosa, black cohosh
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing